anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Although endovascular treatment (EVT) has developed and still progressing, calcified lesions remain a big challenge to operators in obtaining good results. Whenever, the eccentric and calcified plaques or nodules are present, balloon dilatation may be difficult and vascular complications may frequently occur. We present a 73-year-old woman, with severe, eccentric, calcified lesion in the right superficial femoral artery (SFA). First, we performed the aggressive wire recanalization in calcified atheroma and dilatation (ARCADIA) technique for the eccentric plaques. Then, we used a WingmanⓇ crossing catheter (ReFlow Medical, Inc.) to penetrate and pass through the calcifications and eventually exchanged to a ParachuteⓇ (Good Care, Inc.) filter wire. Finally, we performed rotational atherectomy using the JETSTREAMⓇ (Boston Scientific) rotational atherectomy device for debulking to obtain good lesion expansion and was able to avoid potential complications. Performing ARCADIA technique then using a Wingman catheter for inserting a filter wire before JETSTREAMⓇ atherectomy is safe and effective for heavily calcified, eccentric lesions. Further studies will be needed to validate the safety and efficacy of this approach.
Isolated, cloned recombinant or synthetic DNA sequence encoding acidic or basic mammalian fibroblast growth factors (FGF) are claimed. A DNA sequence, defined above, and including a DNA encoding a heterologous signal sequence upstream of, and operably linked to, the DNA encoding the FGF is also new. It may be operably linked to control sequences for expression. Recombinant host cells transformed with the DNA sequence are claimed. Recombinant vector contg., and effective in expressing, isolated etc. DNA sequence, the DNA sequence encoding FGF being operably linked to control sequences compatible with bacteria or mammalina hosts, is claimed. Prodn. of acidic or basic mammalian FGF comprises cultivation of transformed cells is claimed. Human basic FGF inpurified or recombinant form is claimed.
Pulmonary hypertension (PH) pathogenesis is driven by inflammatory and metabolic derangements as well as glycolytic reprogramming. Induction of both interleukin 6 (IL6) and transglutaminase 2 (TG2) expression participates in human and experimental cardiovascular diseases. However, little is known about the role of TG2 in these pathologic processes. The current study aimed to investigate the molecular interactions between TG2 and IL6 in mediation of tissue remodeling in PH. A lung-specific IL6 over-expressing transgenic mouse strain showed elevated right ventricular (RV) systolic pressure as well as increased wet and dry tissue weights and tissue fibrosis in both lungs and RVs compared to age-matched wild-type littermates. In addition, IL6 over-expression induced the glycolytic and fibrogenic markers, hypoxia-inducible factor 1α, pyruvate kinase M2 (PKM2), and TG2. Consistent with these findings, IL6 induced the expression of both glycolytic and pro-fibrogenic markers in cultured lung fibroblasts. IL6 also induced TG2 activation and the accumulation of TG2 in the extracellular matrix. Pharmacologic inhibition of the glycolytic enzyme, PKM2 significantly attenuated IL6-induced TG2 activity and fibrogenesis. Thus, we conclude that IL6-induced TG2 activity and cardiopulmonary remodeling associated with tissue fibrosis are under regulatory control of the glycolytic enzyme, PKM2.
Pain is an inherently negative perceptual and affective experience that acts as a warning system to protect the body from injury and illness. Pain unfolds over time and is influenced by myriad factors, making it highly dynamic. Despite this, statistical measures often treat any intraindividual variability in pain ratings as noise or error. This is consequential, especially for research on chronic pain, because pain variability is associated with greater pain severity and depression. Yet, differences in pain variability between patients with chronic pain and controls in response to acute pain has not been fully examined-and it is unknown if dispositional factors such as pain catastrophizing (negative cognitive-affective response to potential or actual pain in which attention cannot be diverted away from pain) relate to pain variability. In the current study, we recruited chronic-pain patients (N = 30) and pain-free controls (N = 22) to complete a 30-second thermal pain task where they continually rated a painful thermal stimulus. To quantify pain variability and capture potential dynamics, we used both a traditional intraindividual standard deviation (iSD) metric of variability and a novel derivatives approach. For both metrics, patients with chronic pain had higher variability in their pain ratings over time, and pain catastrophizing significantly mediated this relationship. This suggests patients with chronic pain experience pain stimuli differently over time, and pain catastrophizing may account for this differential experience. PERSPECTIVE: The present study demonstrates (using multiple variability metrics) that chronic pain patients show more variability when rating experimental pain stimuli, and that pain catastrophizing helps explain this differential experience. These results provide preliminary evidence that short-term pain variability could have utility as a clinical marker in pain assessment and treatment.
The present invention relates to a monochain antibody with dual specificities, which is combined by the monochain antibodies SZ-2 and SZ-21 which respectively have specific combining activity on the glucoprotein GPIb alpha and GPIIIa of the surface of platelets. The monochain antibody with the dual specificities of the present invention simultaneously has the dual activity of the monochain antibodies SZ-2 and the SZ-21. A platelet starting activating section (i.e. an adhesion function of the platelets) can be inhibited, and the final forming process (i.e. a platelet aggregation function) of thrombus can be inhibited. Thus, the novel monochain antibody of the present invention, which is used as new thrombus resistant substitute medicine, has the advantages which are better than those of conventional thrombus resistant medicine and potential application value.
PROBLEM TO BE SOLVED: To obtain a caries resisting agent obtained easily and at a low cost from an agricultural waste material, suppressing the generation of glucan from sucrose by a streptococcus in a mouth cavity, and useful for a food and a beverage by using a fraction extracted from a bagasse with an alkaline agent as an active ingredient. SOLUTION: This caries resisting agent uses a fraction obtained by extracting 1 pt.wt. solid portion of a bagasse such as a sugar cane bagasse produced as a byproduct in the production of a raw sugar from the sugar cane with 1-50 pt.wt. 0.05-2.0 N sodium hydroxide or potassium hydroxide aqueous solution, as an active ingredient. Further, it is preferable to blend 0.1-50 pt.wt. caries resisting agent with 100 pt.wt. caries forming component for preparing a food and beverage capable of suppressing the caries forming property.
Endoscopic submucosal dissection (ESD) has emerged as a new endoscopic technique that allows en-bloc resection of GI lesions, irrespective of size. The most common complications of the ESD techniques are bleeding and perforation. Several reports have shown that if prophylactic closure of a mucosal defect with clips would reduce the risk of bleeding following endoscopic intervention by ESD. With the advancements in endoscopic therapy, various techniques for prevention of post-ESD complications have been reported. However, there have some limitations including their inability to close large defects and the complexity of the approaches and the need for expensive equipment to complete the procedure. To address these issues, we have devised a novel endoscopic barbed-clips suturing method for mucosal defect closure after endoscopic submucosal dissection of colon. In this study, we assessed the technical feasibility of this novel technique.
Prognostic models can strongly support individualized care provision and well-informed shared decision making. There has been an upsurge of prognostic research in the field of nephrology, but the uptake of prognostic models in clinical practice remains limited. Therefore, we map out the research field of prognostic models for kidney patients and provide directions on how to proceed from here. We performed a scoping review of studies developing, validating, or updating a prognostic model for patients with CKD. We searched all published models in PubMed and Embase and report predicted outcomes, methodological quality, and validation and/or updating efforts. We found 602 studies, of which 30.1% concerned CKD populations, 31.6% dialysis populations, and 38.4% kidney transplantation populations. The most frequently predicted outcomes were mortality ( n =129), kidney disease progression ( n =75), and kidney graft survival ( n =54). Most studies provided discrimination measures (80.4%), but much less showed calibration results (43.4%). Of the 415 development studies, 28.0% did not perform any validation and 57.6% performed only internal validation. Moreover, only 111 models (26.7%) were externally validated either in the development study itself or in an independent external validation study. Finally, in 45.8% of development studies no useable version of the model was reported. To conclude, many prognostic models have been developed for patients with CKD, mainly for outcomes related to kidney disease progression and patient/graft survival. To bridge the gap between prediction research and kidney patient care, patient-reported outcomes, methodological rigor, complete reporting of prognostic models, external validation, updating, and impact assessment urgently need more attention.
STUDY OBJECTIVES: In this study we aimed to conduct a comprehensive review of sleep medicine in Iran, focusing on the country's advancements, challenges, and the global context.
METHODS: We conducted a comprehensive review of sleep medicine in Iran, using various sources to ensure a thorough analysis. The national educational curriculum for sleep medicine and guidelines on sleep clinics issued by Iran's Ministry of Health served as a foundational resource. Additionally, we gathered information from the Iranian Sleep Medicine Society website and relevant committee data sources. To enhance our understanding of the current research landscape, we performed a targeted search on PubMed using keywords related to sleep and Iran.
RESULTS: The study presents a dynamic overview of sleep medicine in Iran, highlighting key advancements and challenges. Significant progress was observed in establishing standardized sleep medicine training and accredited sleep clinics. The Iranian Sleep Medicine Society plays a pivotal role in spearheading these developments, contributing to implementing regional guidelines for sleep tests. However, challenges such as a limited number of trained specialists, a scarcity of certified sleep clinics, and obstacles to accessing sleep disorder treatments were identified.
CONCLUSIONS: We advocate for the implementation of increased research initiatives, nationwide education and screening programs, and proactive measures to strengthen the landscape of sleep and circadian medicine in the country.
CITATION: Behkar A, Amirifard H, Samadi S, et al. Global practice of sleep medicine: Iran. J Clin Sleep Med. 2024;20(6):1009-1015.
Post-Infection participants will be identified through Best Practice Alerts through EPIC, and referrals from hospitalist and gastroenterology inpatient services. Post-Infection cohorts will be approached up to 6 weeks after they are released from the hospital, to ensure they are healthy enough to participate.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, dentistry and can be used for treatment of inflammatory periodontal diseases. Luminol-dependent chemiluminescence of oral fluid is carried out. Rate of maximum flash and glow light sum is estimated. With the value of maximum flash from 0.8 to 5 c.u. (conventional units) and light sum of 1.5 to 37 c.u. an impact of magneto-infrared laser radiation is conducted. The impact is conducted with a pulse repetition rate of 80 Hz, LED radiating power of 90 mW. The impact is conducted in area of projection of the foci and in field of angle of the mandible on the same side with exposure 2 minutes per point, and then in the spinous process of third cervical vertebra during 1 minute and in oral tissues for 2 minutes. After that it is affected with magneto-infrared laser radiation with frequency of 150 Hz, LED radiating power of 50 mW. The impact is conducted on reflex points GI4 and E36 symmetrically, VC12 or MC6 and RP6 symmetrically, VC12, alternating every other day. At the same time in each session an effect is exerted on points CI 1, GI 20, E 5, V 10. The treatment course is 10 procedures. Exposure is 0.5 minutes on one point. At the maximum flash rate from 6.55 to 25 c.u. and light sum from 26 to 45 c.u. a biologically active food supplement "PropoFlan" is administered in a dose of 2 tablets 3 times a day for 1 month. ^ EFFECT: method provides choice of adequate treatment of inflammatory periodontal diseases taking into account the activity of oxidative processes in oral fluid. ^ 2 ex
FIELD: medicine, oncology. SUBSTANCE: method deals with treating penis cancer at different stages of tumor process. During operation it is suggested to conduct penis amputation, suture cavernous bodies, then penis skin is shifted towards its root and 1 ml indigo carmine is injected 1 cm proximally against the amputation line along dorsal penis surface, under a surface fascia. Then, 2 min later a surface fascia is lanced to isolate a contrasted lymph vessel and puncture it with a thin needle and an antitumor preparation bleomycin is injected at 50 mg/10 ml Ringer's solution slowly, for 2 min and operation is considered to be over. The method enables to decrease metastases into inguinal lymph nodes till complete regression, and in case of local process - improve sanitary conditions of lymph outflow. EFFECT: higher efficiency of operation. 1 ex
Safety and effectiveness of APTIOM have been established in the age groups 4 to 17 years. Use of APTIOM in these age groups is supported by evidence from adequate and well-controlled studies of APTIOM in adults with partial-onset seizures, pharmacokinetic data from adult and pediatric patients, and safety data from clinical studies in 393 pediatric patients 4 to 17 years of age [see Adverse Reactions (6.1) and Clinical Pharmacology (12.3)]. 

Safety and effectiveness in pediatric patients below the age of 4 years have not been established. 

Animal Data

In a juvenile animal study in which eslicarbazepine acetate (40, 80, 160 mg/kg/day) was orally administered to young dogs for 10 months starting on postnatal day 21, adverse effects on bone growth (decreased bone mineral content and density) were seen in females at all doses at the end of the dosing period, but not at the end of a 2-month recovery period. Convulsions were seen at the highest dose tested. A no-effect dose for adverse effects in juvenile dogs was not identified. The lowest dose tested is less than the maximum recommended pediatric dose (1200 mg/day) on a body surface area (mg/m2) basis. 

A separate juvenile animal study was conducted to assess possible adverse effects on the immune system. Eslicarbazepine acetate (10, 40, 80 mg/kg/day) was orally administered to young dogs for 17 weeks starting on postnatal day 21. No effects on the immune system were observed.
The psychopharmacological treatment of patients with schizophrenia or depression is often accompanied by serious side effects. In particular, the clinical findings of weight gain are worrying, as this side effect can lead to various medical sequelae in the future. However, the treatment of metabolic changes in psychiatric patients is often neglected or unsuccessful. An improved knowledge of possible therapeutic approaches is needed. The aim of this study was to provide an overview of the utilisation and effectiveness of probiotics in reducing weight gain in patients with severe mental illness. A scoping review of studies published until 15 June 2022 was conducted to identify studies using probiotics in people with schizophrenia or depression. We systematically searched the databases EMBASE, PubMed (MEDLINE), Web of Science and SCOPUS with a predefined search string. In addition, reference lists of relevant publications were examined for additional studies. The studies were assessed by two reviewers. The primary outcomes were weight-related measurements. The secondary outcomes were metabolic blood parameters and gut microbiota. Four studies ultimately met the inclusion criteria. Two studies in which probiotics were administered did not find significant effects on pharmacologically induced weight gain. The other two studies examined the effects of synbiotics (a combination of probiotics and prebiotics). Interestingly, less weight gain was observed in individuals with this combined intervention. Adjustments in diet can be helpful and are generally well-accepted interventions in the fight against pharmacologically induced weight gain. The clinical use of probiotics and prebiotics (or synbiotics) as dietary interventions may represent a promising additional strategy in this regard. However, the few studies available showed no clear conclusions.
INTRODUCTION: Harlequin syndrome (HS) is an uncommon condition affecting the sympathetic nervous system, characterized by asymmetrical flushing and sweating impairment, which can affect the face or half of the body. When the dysfunction results from external factors like damage or compression, it's referred to as Harlequin Sign. Our objective was to document an exceedingly rare presentation of Harlequin Sign caused by a T3-T4 paravertebral mass and conduct the first systematic literature review on this subject.
METHODS: We conducted a systematic review of English-language studies using PubMed, Scopus, and Embase databases. We excluded abstracts, posters, congenital and idiopathic Harlequin Syndrome cases, as well as iatrogenic and secondary Harlequin Sign cases related to pathologies other than upper thoracic lesions.
RESULTS: We employed the PRISMA protocol and reviewed 1,538 papers, identifying 8 single case reports describing the Harlequin sign resulting from upper thoracic paravertebral lesions. The mean age of the patients was 41.25 years, with 6 (75 %) being female. The average time from onset to presentation was 8 months, and all patients (100 %) exhibited hemifacial flushing, while 4 (50 %) also had hemifacial anhidrosis. Stress or exercise exacerbated these symptoms in 50 % of cases. Additionally, 3 patients (37.5 %) presented with associated Horner Syndrome. The most commonly used diagnostic tool was a CT scan (50 %), revealing an average tumor diameter of 3.95 cm, with 50 % of cases located at T2-T3. Diagnosis indicated 57 % of cases as schwannomas and 29 % as lung adenocarcinoma (Superior Sulcus). Unfortunately, surgical treatment resolved symptoms in only 25 % of patients.
CONCLUSIONS: Hemifacial or hemibody autonomic symptoms should raise concern for paraspinal lesions in the thoracic spine. In addition to the first comprehensive review on this topic, we present a rare case of a T3/4 paraspinal schwannoma causing Harlequin Syndrome successfully managed with neurosurgical intervention.
In acute hospitalized severe, steroid refractory UC, only two medical rescue therapies have been found efficacious in controlled trials and recommended in management, infliximab and cyclosporine. Due to toxicity and nuance in using cyclosporine, infliximab is by far the most commonly used medical rescue therapy in this setting. There is emerging retrospective and prospective case series data suggesting JAK inhibitors, such as tofacitinib or upadacitinib, could also be used for this patient population. JAK inhibitors offer potential advantages including convenience of oral therapy, efficacy independent of serum albumin levels, and no concern for immunogenicity as is seen with anti-TNFs. They also offer a short half-life and are eliminated by humans within 48 hours of the last dose administered. This could be beneficial, as it may offer a chance to use a JAK inhibitor first and switch to infliximab in patients who do not respond to a JAK inhibitor, as theoretically cumulative immunosuppression should not be as high transitioning from a JAK inhibitor to infliximab, as compared to using JAK inhibitor after infliximab failure since there will still be lots of infliximab present owing to its long half-life. It is unclear how JAK inhibitors compare to our standard of care and where they should be positioned in acute severe UC. This study aims to examine patients with acute severe UC who are refractory to intravenous corticosteroids and determine whether a strategy of using upadacitinib first followed by infliximab in upadacitinib non-responders is non-inferior to conventional management with infliximab only.
FIELD: food and pharmaceutical industries, and feed production. SUBSTANCE: solubilizate of fat- soluble vitamin with surfactants with GLB 10-17 is prepared by codissolution under normal conditions is organochlorine solvents or toluene, then absorbed on water-soluble (but nonsoluble in solvent) powdery support at 60-75 C. Solubilizate comprises fat-soluble vitamins, surfactants and solvent at ratio of 1-0.8: 1.5-10-40. Support including water-soluble powdery vitamins are added in amount to prepare -10% fat-soluble vitamins. This makes it possible to simplify method of transforming fat-soluble vitamins into aqueous dispersive form. EFFECT: more efficient preparation method. 3 cl, 6 ex
Bupropion hydrochloride extended-release tablets, USP (XL) is an antidepressant of the aminoketone class, is chemically unrelated to tricyclic, tetracyclic, selective serotonin reuptake inhibitor, or other known antidepressant agents. Its structure closely resembles that of diethylpropion; it is related to phenylethylamines. It is designated as (±)-1-(3-chorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone hydrochloride. The molecular weight is 276.2. The molecular formula is C13H18ClNO•HCl. Bupropion hydrochloride, USP powder is white, crystalline, and highly soluble in water, in 0.1 N hydrochloric acid, and in alcohol. It has a bitter taste and produces the sensation of local anesthesia on the oral mucosa. The structural formula is:

Each bupropion hydrochloride extended-release tablets, USP (XL) intended for oral administration contains 150 mg or 300 mg of bupropion hydrochloride. In addition, each tablet contains the following inactive ingredients: ethyl cellulose, hypromellose, magnesium stearate, methacrylic acid copolymer dispersion, polyethylene glycol, povidone, silicon dioxide, triethyl citrate. The tablet is printed with black pharmaceutical ink which contains ammonium hydroxide, butyl alcohol, iron oxide black, isopropyl alcohol, propylene glycol and shellac.

The insoluble shell of the extended-release tablet may remain intact during gastrointestinal transit and is eliminated in the feces.

The Product meets USP Dissolution Test 26.
Healthy Adult aged 18-55 years will undergo a single blood collection by the way of vein puncture. Microfluidic techniques, utilizing whole blood, will be employed to evaluate the genomic profile and functional capacity of immune cells. Adjuvant drugs will be employed ex-vivo to determine if adjuvant therapies change genomic expression and bolster immune function.
Romiplostim at the assigned dose will be administered subcutaneously (SQ) once a week for 6 weeks (i.e. 6 doses) unless platelet count exceeds 100 x 10\^9/L and at least 4 doses of therapy were given.After the initial dose, subsequent doses will be administered within a window of +/- 3 days.